BMRN vs. NBIX

Last updated Apr 2, 2026

Compare and contrast key facts about BioMarin Pharmaceutical Inc. (BMRN) and Neurocrine Biosciences, Inc. (NBIX).

Performance

BMRN vs. NBIX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioMarin Pharmaceutical Inc. (BMRN) and Neurocrine Biosciences, Inc. (NBIX). The values are adjusted to include any dividend payments, if applicable.

BMRN vs. NBIX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BMRN BioMarin Pharmaceutical Inc.	-3.69%	-9.58%	-31.83%	-6.83%	17.14%	0.75%	3.71%	-0.70%	-4.51%	7.64%
NBIX Neurocrine Biosciences, Inc.	-6.54%	3.90%	3.60%	10.31%	40.24%	-11.14%	-10.83%	50.53%	-7.96%	100.49%

Fundamentals

Market Cap BMRN : $11.30B NBIX : $13.59B
EPS BMRN : $1.79 NBIX : $4.69
PE Ratio BMRN : 32.05 NBIX : 28.25
PEG Ratio BMRN : 1.92 NBIX : 0.56
PS Ratio BMRN : 3.47 NBIX : 4.73
PB Ratio BMRN : 1.86 NBIX : 4.18
Total Revenue (TTM) BMRN : $3.22B NBIX : $2.86B
Gross Profit (TTM) BMRN : $2.48B NBIX : $2.81B
EBITDA (TTM) BMRN : $613.03M NBIX : $719.10M

Returns By Period

In the year-to-date period, BMRN achieves a -3.69% return, which is significantly higher than NBIX's -6.54% return. Over the past 10 years, BMRN has underperformed NBIX with an annualized return of -3.84%, while NBIX has yielded a comparatively higher 12.30% annualized return.

BMRN

• 1D: 1.33%
• 1M: -4.18%
• YTD: -3.69%
• 6M: 4.34%
• 1Y: -15.75%
• 3Y*: -16.19%
• 5Y*: -5.96%
• 10Y*: -3.84%

NBIX

• 1D: 0.62%
• 1M: 0.14%
• YTD: -6.54%
• 6M: -3.24%
• 1Y: 23.89%
• 3Y*: 9.41%
• 5Y*: 6.19%
• 10Y*: 12.30%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BMRN vs. NBIX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BMRN

BMRN Risk / Return Rank: 19
BMRN Sharpe Ratio Rank: 21
BMRN Sortino Ratio Rank: 19
BMRN Omega Ratio Rank: 20
BMRN Calmar Ratio Rank: 13
BMRN Martin Ratio Rank: 20

NBIX

NBIX Risk / Return Rank: 61
NBIX Sharpe Ratio Rank: 66
NBIX Sortino Ratio Rank: 58
NBIX Omega Ratio Rank: 60
NBIX Calmar Ratio Rank: 61
NBIX Martin Ratio Rank: 62

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BMRN vs. NBIX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BioMarin Pharmaceutical Inc. (BMRN) and Neurocrine Biosciences, Inc. (NBIX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BMRN	NBIX	Difference
Sharpe ratio Return per unit of total volatility	-0.45	0.71	-1.16
Sortino ratio Return per unit of downside risk	-0.48	1.13	-1.62
Omega ratio Gain probability vs. loss probability	0.94	1.16	-0.22
Calmar ratio Return relative to maximum drawdown	-0.77	0.95	-1.72
Martin ratio Return relative to average drawdown	-1.12	2.31	-3.44
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BMRN vs. NBIX - Sharpe Ratio Comparison

The current BMRN Sharpe Ratio is -0.45, which is lower than the NBIX Sharpe Ratio of 0.71. The chart below compares the historical Sharpe Ratios of BMRN and NBIX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BMRN	NBIX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.45	0.71	-1.16
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.19	0.19	-0.38
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.11	0.31	-0.42
Sharpe Ratio (All Time) Calculated using the full available price history	0.12	0.13	-0.02

Correlation

The correlation between BMRN and NBIX is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BMRN vs. NBIX - Dividend Comparison

Neither BMRN nor NBIX has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

BMRN vs. NBIX - Drawdown Comparison

The maximum BMRN drawdown since its inception was -90.58%, smaller than the maximum NBIX drawdown of -97.21%. Use the drawdown chart below to compare losses from any high point for BMRN and NBIX.

Drawdown Indicators

	BMRN	NBIX	Difference
Max Drawdown Largest peak-to-trough decline	-90.58%	-97.21%	+6.63%
Max Drawdown (1Y) Largest decline over 1 year	-24.68%	-20.90%	-3.78%
Max Drawdown (5Y) Largest decline over 5 years	-56.12%	-42.89%	-13.23%
Max Drawdown (10Y) Largest decline over 10 years	-60.73%	-46.39%	-14.34%
Current Drawdown Current decline from peak	-61.62%	-14.82%	-46.80%
Average Drawdown Average peak-to-trough decline	-45.39%	-44.05%	-1.34%
Ulcer Index Depth and duration of drawdowns from previous peaks	16.93%	8.59%	+8.34%

Volatility

BMRN vs. NBIX - Volatility Comparison

BioMarin Pharmaceutical Inc. (BMRN) has a higher volatility of 7.98% compared to Neurocrine Biosciences, Inc. (NBIX) at 6.97%. This indicates that BMRN's price experiences larger fluctuations and is considered to be riskier than NBIX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BMRN	NBIX	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.98%	6.97%	+1.01%
Volatility (6M) Calculated over the trailing 6-month period	25.07%	23.03%	+2.04%
Volatility (1Y) Calculated over the trailing 1-year period	35.69%	33.89%	+1.80%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	32.18%	32.22%	-0.04%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	35.64%	39.43%	-3.79%

Financials

BMRN vs. NBIX - Profitability Comparison

The chart below illustrates the profitability comparison between BioMarin Pharmaceutical Inc. and Neurocrine Biosciences, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

BMRN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, BioMarin Pharmaceutical Inc. reported a gross profit of 579.47M and revenue of 874.57M. Therefore, the gross margin over that period was 66.3%.

NBIX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a gross profit of 787.90M and revenue of 805.50M. Therefore, the gross margin over that period was 97.8%.

BMRN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, BioMarin Pharmaceutical Inc. reported an operating income of 79.39M and revenue of 874.57M, resulting in an operating margin of 9.1%.

NBIX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported an operating income of 210.90M and revenue of 805.50M, resulting in an operating margin of 26.2%.

BMRN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, BioMarin Pharmaceutical Inc. reported a net income of -46.57M and revenue of 874.57M, resulting in a net margin of -5.3%.

NBIX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Neurocrine Biosciences, Inc. reported a net income of 153.70M and revenue of 805.50M, resulting in a net margin of 19.1%.